Tag: nevin manimala

Jpn J Clin Oncol. 2026 Mar 20;56(Supplement_1):i44-i55. doi: 10.1093/jjco/hyaf020.

ABSTRACT

BACKGROUND: Pancreatic and liver cancers are the 6th and 7th most common cancers in Japan and are major contributors to cancer mortality.

METHODS: We used CONCORD-3 data to estimate survival for primary pancreas and liver cancers, registered in 16 population-based regional cancer registries. Five-year net survival was estimated with the Pohar Perme estimator for three periods (2000-2004, 2005-2009, 2010-2014), adjusted for age using International Cancer Survival Standard weights.

RESULTS: We analysed data on 79 636 patients with pancreatic cancer and 122 792 patients with liver cancer. Carcinoma accounted for 91.4% of pancreatic cancers, and age-standardized 5-year net survival remained poor, from 6.4% (95% CI: 5.9%-6.9%) in 2000-2004 to 8.3% (7.8%-8.7%) in 2010-2014. Five-year net survival for localized disease increased slightly, from 39.3% (33.4%-45.2%) in 2000-2004 to 44.2% (36.8%-51.7%) in 2010-2014. Distant-stage pancreatic cancer survival remained <2% throughout 2000-2014. Hepatocellular carcinoma accounted for 83.7% of liver cancers. Five-year net survival increased from 27.4% (26.8%-28.1%) in 2000-2004 to 33.4% (32.7%-34.0%) in 2010-2014. Five-year net survival for localized liver cancer increased from 38.0% (35.3%-40.7%) in 2000-2004 to 48.8% (46.4%-51.3%) in 2010-2014, while distant-stage survival remained <5% throughout 2000-2014.

CONCLUSIONS: Five-year net survival remained poor for patients with pancreatic cancer in Japan throughout 2000-2014. Survival for liver cancer improved slightly. Early detection and improved diagnostic methods may help in reduce the proportion of patients diagnosed with advanced-stage.

PMID:41859888 | DOI:10.1093/jjco/hyaf020

Jpn J Clin Oncol. 2026 Mar 20;56(Supplement_1):i17-i24. doi: 10.1093/jjco/hyaf159.

ABSTRACT

BACKGROUND: We assessed trends and international comparisons of net survival for patients with esophageal cancer using data from Japanese regional population-based cancer registries participating in the CONCORD-3 study.

METHODS: The analysis included 63 631 patients aged 15-99 years diagnosed with esophageal cancer during 2000-14, with follow-up completed either 5 years after diagnosis or by 31 December 2014. Five-year net survival was estimated using the Pohar Perme estimator, by sex, anatomical subsite, calendar period of diagnosis, and extent of disease. Survival estimates were age-standardized using the International Cancer Survival Standard weights.

RESULTS: During 2000-14, the age-standardized 5-year net survival for esophageal cancer improved from 27.7% (95% CI: 26.4%-29.0%) in 2000-04 to 36.0% (34.8%-37.3%) in 2010-14. This increase corresponded with a higher proportion of patients with localized disease. In 2010-14, survival was notably higher among women, at 42.6% (39.7%-45.5%), than among men, at 36.0% (34.8%-37.3%), and among patients aged 45-54 years at 39.7% (35.5%-44.0%), 55-64 years at 38.9% (37.0%-40.8%), and 65-74 years at 39.4% (37.8%-41.1%). Survival remained lower among the oldest patients, aged 75-99 years, at 29.0% (27.0%-31.0%). By anatomical subsite, survival was highest for the “abdominal, or lower third” segment of the esophagus, followed by the “thoracic, or middle third,” while the “cervical, or upper third” showed the lowest survival.

CONCLUSION: Survival for esophageal cancer in Japan has improved, largely attributable to early detection. Variations by sex, age, and subsite were evident. Detailed analyses using population-based registry data will provide evidence to aid the development of effective cancer control strategies.

PMID:41859887 | DOI:10.1093/jjco/hyaf159

Jpn J Clin Oncol. 2026 Mar 20;56(Supplement_1):i87-i93. doi: 10.1093/jjco/hyaf021.

ABSTRACT

BACKGROUND: We aimed at assessing 15-year trends in 5-year net survival for men diagnosed with prostate cancer during 2000-2014 and registered by 16 Japanese regional population-based cancer registries included in the CONCORD-3 study.

METHODS: We included data on adult men (15-99 years) diagnosed with prostate cancer during 2000-2014 and followed-up to 31 December 2014. We grouped patients into five age groups (15-54, 55-64, 65-74, 75-84, and 85-99 years) and four morphology groups according to the ICD-O-3 classification (epithelial, neuroendocrine, other specified morphologies, and malignant neoplasm, not otherwise specified). We grouped patients by stage at diagnosis into localized, regional, and advanced disease. We estimated 5-year net survival by age group, morphological subtype and stage using the Pohar Perme estimator, correcting for background mortality. All-ages estimates were standardized with the International Cancer Survival Standard weights.

RESULTS: Age-standardized 5-year net survival increased over time, from 85.9% in 2000-2004 to 93.0% in 2010-2014. Survival was higher than 90% for epithelial tumors, and for localized and regional disease. Five-year net survival for patients with distant metastasis was poor at 47.3% (95% CI. 39.4-55.1%) during 2010-2014.

CONCLUSIONS: The improvement in survival for prostate cancer may be due to the high and increasing proportion of patients with localized disease and with epithelial tumors, for which 5-year survival approaches 100%. A comprehensive analysis of long-term survival over a longer period of time would be essential to investigate further the factors contributing to the increasing trend in survival.

PMID:41859886 | DOI:10.1093/jjco/hyaf021

Jpn J Clin Oncol. 2026 Mar 20;56(Supplement_1):i116-i125. doi: 10.1093/jjco/hyaf143.

ABSTRACT

BACKGROUND: We assessed survival trends for children with brain tumors, acute lymphoblastic leukemia (ALL), and lymphomas from 16 Japanese regional population-based cancer registries participating in CONCORD-3.

METHODS: We analyzed data for children (0-14 years) diagnosed with a brain tumor, ALL, or lymphoma during 2000-14, with follow-up for at least 5 years after diagnosis or through 31 December 2014. Five-year net survival was estimated by calendar period of diagnosis, age group, and morphology group (for brain tumors), using the Pohar Perme estimator, and age standardized by assigning equal weights to the three age-specific estimates (0-4, 5-9, 10-14 years).

RESULTS: Data on children with a brain tumor (n = 1293), ALL (1438), or lymphoma (508) were eligible. During 2010-14, age-standardized 5-year net survival was 69.6% for brain tumors, 87.6% for ALL, and 89.6% for lymphomas. Survival for ALL was 79.7% in 2000-4, and 87.6% in 2010-14. There were no notable trends for brain tumors or lymphomas. Point estimates of survival for these three childhood cancers in Japan were lower than in several of the Western countries that participated in CONCORD-3.

CONCLUSIONS: The improved survival for ALL probably reflects improved treatment, whereas the lack of improvement for brain tumors may reflect the difficulty in developing more effective treatment strategies for these aggressive tumors. Treatment for lymphomas was established in the 2000s. To evaluate cancer care for children in Japan, we need to continue to monitor survival, using population-based cancer registry data.

PMID:41859885 | DOI:10.1093/jjco/hyaf143

Jpn J Clin Oncol. 2026 Mar 20;56(Supplement_1):i34-i43. doi: 10.1093/jjco/hyaf091.

ABSTRACT

BACKGROUND: We aimed to assess 15-year trends in the 5-year net survival for patients with colon or rectal cancer from 2000 to 2014 and registered in the 16 Japanese regional population-based cancer registries included in the CONCORD-3 study.

METHODS: Data were included for adults (15-99 years) diagnosed with a cancer of the colon or rectum from 2000 to 2014 and followed up until 31 December 2014. We estimated the 5-year net survival by anatomic site, age, and stage using the Pohar Perme estimator. Age-standardized net survival was estimated using the International Cancer Survival Standard weights.

RESULTS: We analyzed data on 247 682 and 102 776 patients with colon and rectal cancer, respectively. Age-standardized 5-year net survival increased from 63.4% (95% CI: 62.7%-64.0%) in 2000-2004 to 67.8% (67.3%-68.4%) in 2010-2014 for colon cancer and from 58.6% (57.6%-59.5%) to 64.8% (64.0%-65.7%) for rectal cancer over the same period. For both cancers, survival was lower for older patients (75-99 years) than other age groups. Five-year net survival was lower for right-sided than left-sided colon cancer. Five-year net survival was higher than 90% for localized cancers of both the colon and rectum throughout 2000-2014. Survival for regional and distant disease for both cancers improved.

CONCLUSIONS: For both colon and rectal cancers, the 5-year net survival improved from 2000 to 2014. However, no improvement was noted for older patients. These results may serve as evidence for developing new cancer control measures and treatment strategies, with a focus on older patients.

PMID:41859884 | DOI:10.1093/jjco/hyaf091

Jpn J Clin Oncol. 2026 Mar 20;56(Supplement_1):i56-i63. doi: 10.1093/jjco/hyaf141.

ABSTRACT

Lung cancer is the leading cause of cancer death worldwide. To aid the development of lung cancer control strategies, we analyzed trends in lung cancer survival using data from 16 population-based cancer registries in Japan that participated in the CONCORD-3 study. We included patients aged 15-99 years diagnosed with lung cancer between 2000 and 2014 and followed up until 31 December 2014. A total of 5-year net survival was estimated using the Pohar Perme estimator, stratified by calendar period, age group, sex, histological subtype, and stage. All-ages estimates were standardized with the International Cancer Survival Standard weights. Age-standardized 5-year net survival in 339 277 patients with lung cancer increased slightly over time, from 29.3% (95% confidence intervals 28.1%-30.5%) for patients diagnosed during 2000-2004 to 32.9% (32.3%-33.4%) in 2010-2014. Five-year net survival improved particularly for young patients (15-44 years), for women diagnosed with non-small cell lung cancer and with localized disease. We observed limited or no survival improvement for patients diagnosed with small-cell lung cancer or with distant disease. In Japan, 5-year net survival for patients with lung cancer improved slightly over the 15 years 2000-2014, but no improvement was observed for patients with small-cell lung cancer or with distant disease. Continued surveillance of cancer survival is essential to guide cancer control efforts and further improve treatment outcomes.

PMID:41859883 | DOI:10.1093/jjco/hyaf141

Jpn J Clin Oncol. 2026 Mar 20;56(Supplement_1):i25-i33. doi: 10.1093/jjco/hyaf130.

ABSTRACT

BACKGROUND: We estimated net survival trends for patients with stomach cancer registered in 16 regional population-based cancer registries in Japan that participated in the CONCORD-3 study.

METHODS: We included data on adults (15-99 years) diagnosed with stomach cancer between 2000 and 2014 and followed-up for their vital status until 31 December 2014. We grouped cancer patients into three anatomic groups (proximal, distal, and overlapping regions and stomach cancer, not otherwise specified) with the International Classification of Disease for Oncology, Third edition topography codes. We estimated 5-year net survival with the Pohar Perme estimator for three calendar periods (2000-2004, 2005-2009, 2010-2014), by age group (15-44, 45-54, 55-64, 65-74, and 75-99 years), anatomic group, and stage at diagnosis. All-ages survival estimates were age-standardized using the International Cancer Survival Standard weights.

RESULTS: Five-year net survival improved over time, from 50.5% in 2000-2004 to 57.6% and 60.3% in 2005-2009 and 2010-2014, respectively. Survival for patients with proximal stomach cancer improved from 49.7% in 2000-2004 to 53.5% 2005-2009 and plateaued to 53.1% in 2010-2014. Survival for distal stomach cancer increased from 64.8% in 2000-2004 to 67.6% and 68.2% in 2005-2009 and 2010-2014, respectively. In 2010-2014, 5-year net survival for patients with localized disease (94.8%) was much higher than survival for regional (53.7%) and distant (6.4%) disease.

CONCLUSIONS: Five-year net survival for stomach cancer improved noticeably during 2000-2014. This improvement might be due to advances in systemic chemotherapy. Although survival in distal stomach cancer had improved, no such improvement was seen in proximal stomach cancer. Standardizing esophagogastric junction cancer treatment may improve its outcomes and contribute to better survival in proximal stomach cancer overall. Scientific evaluation of screening programs is also needed to enhance the efficacy of stomach cancer control initiatives in Japan.

PMID:41859881 | DOI:10.1093/jjco/hyaf130

Jpn J Clin Oncol. 2026 Mar 20;56(Supplement_1):i3-i16. doi: 10.1093/jjco/hyaf203.

ABSTRACT

BACKGROUND: In 2018, CONCORD-3 updated long-term surveillance of cancer survival trends worldwide. In this monograph, we conducted further analyses and examined trends in net survival using the Japanese data during 2000-14.

METHODS: Sixteen population-based cancer registries in Japan contributed data to CONCORD-3 with anonymized individual records on 2 237 861 patients diagnosed with one of 15 adult cancers (15-99 years), and brain tumors and hematological malignancies in children (0-14 years). Five-year net survival was estimated with the Pohar Perme estimator and age-standardized with International Cancer Survival Standard weights. We estimated survival for three calendar periods, by age group, sex, anatomic site or morphology, and by stage at diagnosis.

RESULTS: Five-year net survival improved between 2000-04 and 2010-14 for several cancers, including brain tumors (27.9%-46.3%), ovarian cancer (35.5%-46.3%), stomach cancer (50.5%-60.3%), lymphoid malignancies (47.5%-57.3%), myeloid malignancies (24.8%-33.3%), and esophageal cancer (27.7%-36.0%). Breast cancer, childhood lymphoma, and prostate cancer showed consistently high or improving survival (85.9%-93.0%). In contrast, survival for melanoma remained unchanged. Net survival was low for pancreatic cancer (6.9%-8.3%). Among selected countries, survival was higher in Japan for esophageal (36.0%), liver (30.1%), and lung cancers (32.9%). Survival for melanoma, hematologic malignancies, and childhood cancers was lower in Japan than in Western countries.

CONCLUSIONS: Net survival in Japan improved substantially for several cancers, but survival for pancreatic cancer remained low. International collaboration is crucial to accelerate the development of effective cancer control strategies.

PMID:41859880 | DOI:10.1093/jjco/hyaf203

Jpn J Clin Oncol. 2026 Mar 20;56(Supplement_1):i64-i72. doi: 10.1093/jjco/hyaf019.

ABSTRACT

BACKGROUND: We assessed survival trends and international comparisons of patients with cutaneous melanoma from Japanese regional population-based cancer registries participating in the CONCORD-3 study.

METHODS: Subjects were patients aged 15-99 years diagnosed with cutaneous melanoma during 2000-2014, with follow-up completed either 5 years after diagnosis or through 31 December 2014. Five-year net survival was estimated by morphological type and calendar period of diagnosis, using the Pohar Perme estimator, and age-standardized using the International Cancer Survival Standard weights.

RESULTS: Age-standardized 5-year net survival for cutaneous melanoma remained stable among 4018 eligible subjects as follows: 68.9% during 2000-2004 (862 patients), 68.3% during 2005-2009 (1819 patients), and 69.0% during 2010-2014 (1337 patients). Five-year net survival in 2010-2014 was highest for lentigo maligna melanoma (89.0%, 64 patients, not age-standardized), followed by superficial spreading melanoma (88.4%, 91 patients) and acral lentiginous melanoma (83.7%, 163 patients, not age-standardized). However, survival for malignant melanoma not otherwise specified (68.0%, 1120 patients) and nodular melanoma was lower (56.5%, 58 patients). Five-year net survival for all types of cutaneous melanoma combined during 2010-2014 was lower in Japan (69.0%) and South Korea (59.9%) than in Australia, France, Germany, Italy, UK, Canada and the US (>85.7%).

CONCLUSIONS: International disparities in net survival for cutaneous melanoma may be attributable to differences in the distribution of histological sub-types of melanoma and to variation in the availability and utilization of treatment modalities. Continuous monitoring of cancer survival is crucial for developing effective cancer control strategies.

PMID:41859879 | DOI:10.1093/jjco/hyaf019

Jpn J Clin Oncol. 2026 Mar 20;56(Supplement_1):i94-i102. doi: 10.1093/jjco/hyaf165.

ABSTRACT

BACKGROUND: Brain tumors are a serious health issue, and survival is an effective indicator of how the healthcare system manages them. We examined net survival trends for patients diagnosed with a primary brain tumor during 2000-2014 in Japan, using data from 16 regional population-based cancer registries participating in the CONCORD-3 study.

METHODS: We included patients aged 15-99 years, with follow-up completed either 5 years after diagnosis or up to 31 December, 2014. We estimated 5-year net survival by age group and morphological subtype using the Pohar Perme estimator, and age-standardized with International Cancer Survival Standard weights.

RESULTS: Five-year net survival for brain tumors increased from 27.9% for patients diagnosed during 2000-2004 to 46.3% in 2010-2014. During 2010-2014, 5-year net survival for astrocytic tumors was 22.3%, but ~90% for neuronal and mixed neuro-glial tumors, germ cell tumors, and other specified tumors. Five-year net survival reached 62.1% for oligodendroglial and oligoastrocytic tumors.

CONCLUSIONS: Five-year net survival for brain tumors in Japan improved during 2000-2014, with remarkable variations by morphologic type. Survival improved for all age groups, and particularly for younger patients, highlighting the need for enhanced survivorship care. Japan’s focus on comprehensive data collection and supportive care for longer-term survivors remains key for further progress. When comparedinternationally, Japan’s gains sit at the higher end of reported survival ranges, underscoring how robust registry infrastructure and equitable access to care could inform strategies for brain tumor care.

PMID:41859878 | DOI:10.1093/jjco/hyaf165